Abaloparatide is a synthetic peptide modeled on human parathyroid hormone-related peptide. FDA has approved it for certain women and men with osteoporosis at high risk for fracture. This guide covers its structure, mechanism, label, key trials and regulatory history, checked on November 17, 2026.
Quick answer: Abaloparatide is a prescription peptide drug sold as Tymlos. FDA approved Tymlos on April 28, 2017. It acts like parathyroid hormone at its main receptor and stimulates new bone formation. The label lists hypercalciuria, dizziness, nausea and headache among the most common adverse reactions in women.
Vitrapep does not sell abaloparatide; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is abaloparatide?
Abaloparatide is a synthetic chain of 34 amino acids. The Tymlos label describes it as a “human parathyroid hormone related peptide [PTHrP(1-34)] analog.” An analog is a modified version of a natural molecule, here the first 34 amino acids of PTHrP. The label calls abaloparatide a synthetic peptide, while teriparatide is made in bacteria (Tymlos label).
PubChem lists its formula as C174H300N56O49 and its molecular weight as 3,961 g/mol (PubChem). The label gives the same formula and 3961 daltons. Our page on types of peptides explains how peptides are grouped.
Drugs@FDA lists Tymlos, from Radius, as a Type 1 new molecular entity approved on April 28, 2017 (Drugs@FDA). The label’s initial US approval year is also 2017.
Abaloparatide: key facts
| Fact | Detail |
|---|---|
| Structure | Synthetic 34-amino-acid peptide based on PTHrP(1-34) |
| Class | PTHrP(1-34) analog; PTH1 receptor agonist |
| Molecular formula | C174H300N56O49 (PubChem) |
| Molecular weight | 3,961 g/mol (PubChem); 3961 daltons (label) |
| First FDA approval | April 28, 2017 (Tymlos, new molecular entity) |
| Approved brands | Tymlos (Radius Health) |
How does abaloparatide work?
The label states that abaloparatide “acts as an agonist at the PTH1 receptor (PTH1R).” This is the same receptor used by parathyroid hormone. Binding “results in activation of the cAMP signaling pathway in target cells.” cAMP is a messenger molecule that relays the signal inside the cell.
In bone, the label says abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces. Trabecular bone is the spongy inner bone, as in the spine. Cortical bone is the dense outer shell. For how PTH-family peptides fit with other hormones, see our overview of peptide hormones.
What is abaloparatide approved for?
The current Tymlos label lists two indications (Tymlos label, revised August 2026):
- Tymlos, 2017: “the treatment of postmenopausal women with osteoporosis at high risk for fracture.”
- Tymlos, December 19, 2022: “to increase bone density in men with osteoporosis at high risk for fracture.”
The label defines high risk as a history of osteoporotic fracture or multiple risk factors for fracture. It also covers people who have failed or cannot tolerate other osteoporosis therapy. It states that in postmenopausal women with osteoporosis, Tymlos “reduces the risk of vertebral fractures and nonvertebral fractures.” Drugs@FDA records the men’s indication as a new-indication supplement approved on December 19, 2022.
What did the key trials of abaloparatide show?
ACTIVE (human data). This Phase 3 double-blind trial ran at 28 sites in 10 countries. It randomized 2,463 postmenopausal women to abaloparatide (824), placebo (821) or open-label teriparatide (818) for 18 months. The primary endpoint was new vertebral fractures with abaloparatide versus placebo (Miller et al., 2016; NCT01343004).
The Tymlos label reports new vertebral fractures at 18 months in 0.6% on abaloparatide and 4.2% on placebo. The paper reports greater bone mineral density gains than placebo at the hip, femoral neck and spine. Hypercalcemia occurred in 3.4% on abaloparatide and 6.4% on teriparatide (risk difference −2.96, 95% CI −5.12 to −0.87).
ATOM (human data). This Phase 3 trial randomized 228 men with osteoporosis, 149 to abaloparatide and 79 to placebo. The primary endpoint was change in lumbar spine bone mineral density at 12 months. It rose 8.48% with abaloparatide versus 1.17% with placebo (p < 0.0001). Total hip and femoral neck density also rose more (Czerwinski et al., 2022; NCT03512262). This trial measured bone density, not fractures.
What side effects does the abaloparatide label list?
In postmenopausal women, the label lists hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo as the most common adverse reactions. Rates from the ACTIVE trial, Tymlos versus placebo, include:
- Hypercalciuria: 11% versus 9%.
- Dizziness: 10% versus 6%.
- Nausea: 8% versus 3%.
- Headache: 8% versus 6%.
- Palpitations: 5% versus 0.4%.
In the men’s trial, the most frequent were local site reactions, including redness (13% versus 5%). Dizziness (9% versus 1%) and arthralgia (7% versus 1%) followed.
The current label has no boxed warning. Its warnings cover hypersensitivity reactions, osteosarcoma risk, orthostatic hypotension, hypercalcemia, and hypercalciuria with urolithiasis. The hypersensitivity warning is listed as a recent major change dated August 2026. The label states that “TYMLOS may cause hypercalcemia.”
What is the regulatory status of abaloparatide, and is it used in research?
Abaloparatide is a prescription drug. Drugs@FDA lists Tymlos with prescription marketing status. FDA’s list of Drug Safety Communications, which covers January 2020 to November 2026, includes none for abaloparatide (FDA).
Tymlos launched with a boxed warning on osteosarcoma, a bone cancer. The label reports more osteosarcoma in male and female rats given abaloparatide, rising with exposure. This is animal data. The FDA-approved label revised in December 2021 lists “Osteosarcoma Boxed Warning, Removed 12/2021” (FDA label, 2021). The current label still says “It is unknown whether TYMLOS will cause osteosarcoma in humans.”
WADA’s 2026 Prohibited List does not name abaloparatide or parathyroid hormone. Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections.
In research, abaloparatide is being studied in human trials beyond osteoporosis treatment alone. One Phase 2 trial at Hospital for Special Surgery tests it in people having spinal fusion surgery. Its primary outcome is fusion mass bridging at one year (NCT03841058).
Frequently asked questions about abaloparatide
Is abaloparatide a peptide?
Yes. It is a synthetic 34-amino-acid peptide based on parathyroid hormone-related peptide.
Is abaloparatide the same as teriparatide?
No. Teriparatide copies the first 34 amino acids of parathyroid hormone. Abaloparatide is based on PTHrP. Both act at the PTH1 receptor. See our teriparatide guide.
Does abaloparatide have a boxed warning?
Not anymore. The osteosarcoma boxed warning was removed in December 2021. Osteosarcoma risk remains in the warnings section.
Is abaloparatide approved for men?
Yes. FDA added an indication to increase bone density in men with osteoporosis at high risk for fracture on December 19, 2022.
Is abaloparatide banned in sport?
WADA’s 2026 list does not name it. For another bone peptide, see our calcitonin-salmon guide.
What to know now
- Structure: synthetic 34-amino-acid PTHrP(1-34) analog, about 3,961 g/mol.
- Approval: Tymlos, April 28, 2017; men’s indication added December 19, 2022.
- Mechanism: PTH1 receptor agonist that stimulates new bone formation.
- Evidence: fewer new vertebral fractures than placebo in women; larger spine density gains than placebo in men.
- Safety: no boxed warning since December 2021; hypersensitivity added to warnings in August 2026.
- Sport: not named on the WADA 2026 list.
What we’re watching
The spinal fusion trial, with primary completion estimated for February 2027 (NCT03841058). A Qilu Pharmaceutical Phase 3 trial of its own abaloparatide product in postmenopausal women, listed as not yet recruiting (NCT06898060). And further Tymlos label updates; the latest, dated August 3, 2026, is in Drugs@FDA.